Rare cancers: the greatest inequality in cancer research and oncology treatment
Open Access
- 21 September 2017
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 117 (9) , 1255-1257
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapiesBritish Journal of Cancer, 2017
- Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utilityOncotarget, 2015
- Examining the utility of patient-derived xenograft mouse modelsNature Reviews Cancer, 2015
- Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers InitiativeEuropean Journal of Cancer, 2015
- Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast CancerJNCI: Journal of the National Cancer Institute, 2014
- Evaluating Many Treatments and Biomarkers in Oncology: A New DesignJournal of Clinical Oncology, 2013
- Mucinous and Signet-Ring Cell Colorectal Cancers Differ from Classical Adenocarcinomas in Tumor Biology and PrognosisAnnals of Surgery, 2013
- The Clinical Relevance of Cancer Cell LinesJNCI: Journal of the National Cancer Institute, 2013
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- The Occurrence of Rare Cancers in U.S. Adults, 1995–2004Public Health Reports®, 2010